Related Experiment Video

Updated: May 22, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates

Taketoshi Furugohri1, Toshio Fukuda, Naoki Tsuji

  • 1Biological Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, Japan. furugori.taketoshi.v5@daiichisankyo.co.jp

European Journal of Pharmacology
|May 2, 2012
PubMed

Insights

Low doses of melagatran, a direct thrombin inhibitor, paradoxically worsened blood clotting in rats. In contrast, factor Xa inhibitors like edoxaban showed no such pro-clotting effects, suggesting a lower risk of hypercoagulation.

Area of Science:

  • Pharmacology
  • Hematology
  • Thrombosis Research

Background:

  • Concerns exist regarding anticoagulants paradoxically increasing thrombogenesis.
  • Direct thrombin inhibitors and factor Xa inhibitors are common anticoagulants.
  • Understanding dose-dependent effects is crucial for anticoagulant safety.

Purpose of the Study:

  • To compare the pro-thrombotic potential of direct thrombin inhibition versus factor Xa inhibition.
  • To investigate the dose-dependent paradoxical hypercoagulation effect of melagatran.
  • To evaluate the safety of edoxaban and heparin in a tissue factor-induced hypercoagulation model.

Main Methods:

  • Hypercoagulation was induced in rats by tissue factor injection.
  • Administration of varying doses of melagatran, heparin, and edoxaban.
  • Measurement of platelet consumption and thrombin-antithrombin complex generation.

Main Results:

  • Subtherapeutic concentrations of melagatran significantly enhanced platelet consumption and thrombin generation.
  • High doses of melagatran and other anticoagulants (heparin, edoxaban) did not induce paradoxical hypercoagulation.
  • Melagatran's effect was concentration-dependent, with low levels exacerbating and high levels ameliorating coagulation status.

Conclusions:

  • Subtherapeutic concentrations of direct thrombin inhibitors like melagatran can activate coagulation pathways.
  • Factor Xa inhibition with edoxaban appears to have a lower risk of paradoxical hypercoagulation compared to melagatran.
  • Dose and concentration are critical factors in the safety profile of direct thrombin inhibitors.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.